What we do
Cysbio uses advanced metabolic engineering and synthetic biology approaches to construct bacterial cell factories for transforming the production of biochemicals from renewable feedstocks.
Our proprietary cell factories produce commodity chemicals for existing markets, and Cysbio technologies enable the production of entirely new chemicals with novel properties:
- Amino acids for food, feed and pharma
- Precursors for functional polymers and novel materials
- Modification of pharmaceutical compounds to increase solubility and bioavailability
- Natural biodegradable antifouling agents
Cysbio is a spin-out from the Novo Nordisk Foundation Center for Biosustainability at the Technical University of Denmark.
Products and Technology
Amino acids
We produce selected amino acids through fermentation of microorganisms using proprietary processes that result in unprecedented yields and titers. The amino acids have applications in the multibillion dollar pharma, food and feed markets. The low production cost furthermore enables the use of the compounds in the polymer industry.
Sulfated biochemicals
Cysbio adds novel functionalities to biological chemicals through advanced metabolic and enzyme engineering. Our products are produced by biological processes from renewable carbon sources.
Our patented sulfation technology applies to a wide range of biological chemicals, resulting in novel functionalities.
Cysbio technologies enable the production of biochemicals with improved solubility and bioavailability for the pharmaceutical and technical industries. The sulfated biochemicals will have applications as antibiofouling agents, nutraceutical ingredients and precursors for functional polymers.
- We produce a large portfolio of sulfate esters for use as novel functional polymers with improved properties such as increased fire-resistance, electrical conductivity, functionality for use in fuel cells, and decreased surface adhesion.
- The antibiofouling agent zosteric acid is naturally produced by seagrasses belonging to the genus Zostera. We have developed a method for producing high concentrations of zosteric acid through fermentation of microorganisms.
Team
Henrik Meyer, CEO
(Co-Founder)
Henrik is an agronomist by education, and has worked his entire career in various management positions for biotech companies like Monsanto, Novozymes and Evolva with a focus on leadership, strategy, marketing and business development.
Alex Toftgaard Nielsen, CSO
(Co-Founder, Inventor)
Alex has a background in metabolic engineering, bacterial physiology and synthetic biology. He holds MSc and PhD degrees in Chemical Engineering and Microbiology from the Technical University of Denmark and has received postdoctoral training at Stanford University. He has held positions at companies such as Exiqon (Denmark) and Genencor (USA). Alex is also a Professor at the Novo Nordisk Foundation Center for Biosustainability at the Technical University of Denmark.
Christian Bille Jendresen, Director, Sulfation Technologies
(Co-Founder, Inventor)
Christian is directing research in novel compounds and has a background in biological engineering, synthetic biology and microbial genetics. He holds MSc.Eng. and PhD degrees from the Technical University of Denmark and has experience from the University of Copenhagen, University of Wisconsin-Madison, the National University of Singapore, the University of California Berkeley and Danisco (Dupont).
Hemanshu Mundhada, Director, Amino Acid Technologies
(Co-Founder, Inventor)
Hemanshu is directing research in amino acids and related compounds. After completing his MSc from the Indian Institute of Technology, Bombay, he received his PhD and postdoctoral training in enzyme engineering at Jacobs University Bremen and RWTH Aachen, Germany, respectively. At the Technical University of Denmark, Hemanshu has gained extensive experience in strain engineering and evolution along with fermentation and cell physiology.
Join us
Where are expanding. See our four new job opportunities.
Partnership
We seek collaboration with industry leaders through strategic partnerships for expanding our product portfolio, and to take advantage of the Cysbio technology platform. Cysbio offers extensive expertise in metabolic engineering, synthetic biology and fermentation processes. We see our collaborations as long-term investments in future business development.
Contact
We have relocated from The Novo Nordisk Center for Biosustainability at the Technical University of Denmark campus in Lyngby to our new premises in the DTU Science Park in Hørsholm, Denmark.
Address
Agern Allé 1,
2970 Hørsholm, Denmark
CVR
40270752
E-mail
contact@cysbio.com